

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

### SECTION 1. IDENTIFICATION

Product name : Grazoprevir / Elbasvir Formulation  
Other means of identification : No data available

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Specific target organ toxicity : Category 2 (Liver, Testis)  
- repeated exposure (Oral)

#### GHS label elements

Hazard pictograms : 

Signal Word : Warning

Hazard Statements : H373 May cause damage to organs (Liver, Testis) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**  
P260 Do not breathe dust.  
**Response:**  
P314 Get medical attention if you feel unwell.  
**Disposal:**  
P501 Dispose of contents and container to an approved waste disposal plant.

#### Other hazards

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Cellulose	No data available	9004-34-6	$\geq 5 - < 10$ *
Grazoprevir	No data available	1350462-55-3	$\geq 5 - < 10$ *
Elbasvir	No data available	1370468-36-2	$\geq 1 - < 5$ *
Magnesium stearate	Octadecanoic acid, magnesium salt (2:1)	557-04-0	$\geq 1 - < 5$ *

\* Actual concentration or concentration range is withheld as a trade secret

### SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause damage to organs through prolonged or repeated exposure if swallowed.  
Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.  
No information available.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 08/07/2025
10.0	12/06/2025	76204-00031	Date of first issue: 03/17/2015

---

- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Metal oxides  
Chlorine compounds  
Nitrogen oxides (NOx)
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
- 

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
- 

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
-

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

Local/Total ventilation : Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.  
Advice on safe handling : Use only with adequate ventilation.  
Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.  
Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.  
Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Total dust)	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m <sup>3</sup>	CA BC OEL
		TWAEV (total dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Grazoprevir	1350462-55-3	TWA	260 µg/m <sup>3</sup> (OEB 2)	Internal
Elbasvir	1370468-36-2	TWA	150 µg/m <sup>3</sup> (OEB 2)	Internal
Magnesium stearate	557-04-0	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Inhalable)	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (Respirable)	3 mg/m <sup>3</sup>	CA BC OEL
		TWAEV (inhalable dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWAEV (respirable aerosol fraction)	3 mg/m <sup>3</sup>	CA QC OEL

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder  
Color : white  
Odor : No data available  
Odor Threshold : No data available  
pH : No data available  
Melting point/freezing point : No data available

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 08/07/2025
10.0	12/06/2025	76204-00031	Date of first issue: 03/17/2015

---

Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics Particle size	:	No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac-	:	May form explosive dust-air mixture during processing,

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 08/07/2025
10.0	12/06/2025	76204-00031	Date of first issue: 03/17/2015

---

tions	handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

|| Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

#### Components:

##### **Cellulose:**

|| Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
|| Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
|| Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

##### **Grazoprevir:**

|| Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

##### **Elbasvir:**

|| Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 1,000 mg/kg

##### **Magnesium stearate:**

|| Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials  
|| Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg



# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

---

|| Result : Not a skin sensitizer.

### Elbasvir:

|| Test Type : Local lymph node assay (LLNA)  
|| Routes of exposure : Dermal  
|| Species : Mouse  
|| Result : negative

### Magnesium stearate:

|| Test Type : Maximization Test  
|| Routes of exposure : Skin contact  
|| Species : Guinea pig  
|| Method : OECD Test Guideline 406  
|| Result : negative  
|| Remarks : Based on data from similar materials

### Germ cell mutagenicity

|| Not classified based on available information.

### Components:

#### Cellulose:

|| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
  
|| Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

#### Grazoprevir:

|| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: Chromosome aberration test in vitro  
Result: negative  
  
|| Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Application Route: Oral  
Result: negative  
  
|| Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ  
cell mutagen.

#### Elbasvir:

|| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

---

Genotoxicity in vivo : Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Rat  
Application Route: Oral  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

### Components:

#### Cellulose:

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

### Grazoprevir:

- Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 400 mg/kg body weight  
Result: negative
- Test Type: Multi-generation study  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 400 mg/kg body weight  
Result: No effects on fertility., No effects on fetal development.
- Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Embryo-fetal toxicity.: NOAEL: 200 mg/kg body weight  
Result: No effects on fetal development.
- Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-fetal toxicity.: NOAEL: 200 mg/kg body weight  
Result: No effects on fetal development.
- Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Intravenous  
Embryo-fetal toxicity.: NOAEL: 100 mg/kg body weight  
Result: No effects on fetal development.

### Elbasvir:

- Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Application Route: Oral  
Fertility: NOAEL: 1,000 mg/kg body weight  
Result: No effects on fertility.
- Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight  
Result: No effects on early embryonic development.
- Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight  
Result: No effects on early embryonic development.

### Magnesium stearate:

- Effects on fertility : Test Type: Combined repeated dose toxicity study with the

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

---

reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

May cause damage to organs (Liver, Testis) through prolonged or repeated exposure if swallowed.

### Components:

#### Grazoprevir:

Target Organs : Liver, Testis  
Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Cellulose:

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

#### Grazoprevir:

Species : Rat  
NOAEL : 400 mg/kg  
Application Route : Oral  
Exposure time : 30 Days  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 400 mg/kg  
Application Route : Oral  
Exposure time : 180 Days  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 15 mg/kg  
LOAEL : 100 mg/kg

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

---

Application Route : Oral  
Exposure time : 270 Days  
Target Organs : Liver, Blood, Bone marrow, gallbladder, spleen, Testis

Species : Mouse  
NOAEL : 200 mg/kg  
LOAEL : 500 mg/kg  
Application Route : Oral  
Exposure time : 90 Days  
Target Organs : Liver, Kidney, Blood

Species : Dog  
NOAEL : 20 mg/kg  
LOAEL : 600 mg/kg  
Application Route : Oral  
Exposure time : 30 Days  
Target Organs : Blood, Testis

Species : Monkey  
NOAEL : 10 mg/kg  
Exposure time : 8 Days  
Remarks : No significant adverse effects were reported

### **Elbasvir:**

Species : Rat  
NOAEL : 1,000 mg/kg  
Application Route : Oral  
Exposure time : 180 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 1,000 mg/kg  
Application Route : Oral  
Exposure time : 270 d  
Remarks : No significant adverse effects were reported

### **Magnesium stearate:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

### **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

### **Components:**

#### **Grazoprevir:**

Ingestion : Symptoms: Headache, Gastrointestinal disturbance

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

### Elbasvir:

Ingestion : Symptoms: Headache, Abdominal pain, constipation, Nausea, Fatigue, muscle pain, joint pain, Dizziness, Cough, Skin irritation, rhinitis, Drowsiness, nasal congestion

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

##### Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

##### Grazoprevir:

Toxicity to fish : LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10 mg/l  
Exposure time: 96 h  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility.

LC50 (Americamysis): 8.9 mg/l  
Exposure time: 96 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l  
Exposure time: 72 hrs  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 10 mg/l  
Exposure time: 72 hrs  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.98 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 5 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 1.3 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

### Elbasvir:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 10 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: No toxicity at the limit of solubility.

LC50 (Menidia beryllina (Silverside)): > 10 mg/l  
Exposure time: 96 h  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility.

LC50 (Americamysis): 7.7 mg/l  
Exposure time: 96 h  
Method: US-EPA OPPTS 850.1035  
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (algae)): > 0.081 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.081 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.0023 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.84 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

NOEC: 271.9 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

### **Magnesium stearate:**

- Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.
- Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.
- NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials
- Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

### **Persistence and degradability**

#### **Components:**

##### **Cellulose:**

Biodegradability : Result: Readily biodegradable.

##### **Grazoprevir:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 66 %  
Exposure time: 28 d

##### **Elbasvir:**

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

---

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 37 %  
Exposure time: 28 d

### Magnesium stearate:

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

### Bioaccumulative potential

#### Components:

##### Grazoprevir:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 7.62

Partition coefficient: n-octanol/water : log Pow: 3.72

##### Elbasvir:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 82  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 6.54

##### Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

### Mobility in soil

#### Components:

##### Grazoprevir:

Distribution among environmental compartments : log Koc: 4.01

##### Elbasvir:

Distribution among environmental compartments : log Koc: 5.24

### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version 10.0      Revision Date: 12/06/2025      SDS Number: 76204-00031      Date of last issue: 08/07/2025  
Date of first issue: 03/17/2015

---

### SECTION 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)  
Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

##### IATA-DGR

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Elbasvir)

Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

##### IMDG-Code

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### Domestic regulation

##### TDG

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)  
Class : 9  
Packing group : III  
Labels : 9  
ERG Code : 171  
Marine pollutant : yes(Elbasvir)

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 08/07/2025
10.0	12/06/2025	76204-00031	Date of first issue: 03/17/2015

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## SECTION 15. REGULATORY INFORMATION

### The ingredients of this product are reported in the following inventories:

AICS : not determined

CA. DSL : not determined

IECSC : not determined

### Canadian lists

|| No substances are subject to CEPA Section 84 Ministerial Conditions.

## SECTION 16. OTHER INFORMATION

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)  
CA BC OEL : Canada. British Columbia OEL  
CA QC OEL : Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants  
ACGIH / TWA : 8-hour, time-weighted average  
CA AB OEL / TWA : 8-hour Occupational exposure limit  
CA BC OEL / TWA : 8-hour time weighted average  
CA QC OEL / TWAEV : Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. -

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 08/07/2025
10.0	12/06/2025	76204-00031	Date of first issue: 03/17/2015

---

Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 12/06/2025  
Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8